China Nuvo Solar Energy, Inc. (CNUV) TraderNote CNUV: Well-Supported by Government Efforts and Incentives for Clean Energy Technologies

China Nuvo Solar Energy, Inc. (CNUV) closed yesterday at 0.05, a negative change of 0.01 or a decrease of 9.09 percent from the previous close of 0.06. China Nuvo Solar Energy, Inc. focuses on the development and manufacture of solar cell technology products. It holds rights to solar cell technology relating to a multiple stacked solar cell using waveguide transfers. The companys licensed technology, patented as Photovoltaic cell with integral light transmitting waveguide in a ceramic sleeve, utilizes Cadmium/Tellurium Cadmium/Sulfide powders layered in a ceramic sleeve with a conductive metal back contact. The ceramic sleeve, which serves as a receptacle for the various materials used in the solar cell, eliminates the need for expensive vacuum chambers or a vat with a molten material. A removable lens, clamped on to the cell, gives CNUV the unique ability to repair or add materials to the finished solar cell. Governments worldwide are stepping up efforts to promote renewable clean energy technologies. Government subsidiaries and financial incentives in more than 40 countries around the world are fueling deployment of solar energy installations and creating business opportunities for technology innovators such as CNUV. In yesterday’s daily chart, CNUV’s RSI indicator so far reflects a reading of 36.30 percent, slightly indicating an oversold condition or buying move with the line recently rising above the 30 percent level from below it. MACD indicator with the histogram reading at 0.0 and the 12-day and 26-day EMAs at -0.012 and -0.012, respectively, must completely return above the 0 level to confirm an upward momentum. Slow Stochastic indicator with readings so far of 29.49 %K and 29.42 %D, reflects an oversold condition or buying move with the lines recently rising above the 20 percent level from below it. With share prices hitting the stock’s 52-week low of 0.04 last March 19, a significant support level or buying move was established pushing up prices 25.0 percent to their present level.

Powerwave Technologies, Inc. (PWAV) TraderNote PWAV’s New High Null Fill Antenna Introduced at CTIA Wireless 2008

Powerwave Technologies, Inc. (PWAV) closed yesterday at 2.62, a positive change of 0.09 or an increase of 3.57 percent from the previous close of 2.52. Powerwave Technologies, Inc. supplies wireless solutions for wireless communications networks worldwide. The company designs, manufactures, and markets antennas, boosters, combiners, filters, radio frequency power amplifiers, repeaters, tower-mounted amplifiers, and advanced coverage solutions for use in cellular, PCS, 3G, and WiMax networks. It sells its products through its direct sales force, independent sales representatives, and resellers to wireless original equipment manufacturers and individual wireless network operators. The company was founded in 1985. It was formerly known as Milcom International, Inc. and changed its name to Powerwave Technologies, Inc. in 1996. Powerwave Technologies recently introduced its new high null fill antenna, expanding its growing line-up on antenna solutions at CTIA Wireless 2008, the industrys premier wireless conference and exhibition. Designed for use in suburban and rural areas and with high tower deployments of 20 meters (60 feet) or greater, Powerwaves high null fill supports frequency bands of 1710MHz to 2170MHz. Leveraging Powerwaves patented aperture coupled patch technology and a robust design approach that supports optimal pattern performance including null fill and upper side lobe suppression, the high null fill antenna provides coverage at angles below the main vertical beam for locations where levels of multi-path are low, such as in rural areas. This ensures consistent performance over the entire band, and the elimination of dead zones. In yesterday’s daily chart, PWAV’s RSI indicator so far reflects a reading of 48.98 percent, near the neutral zone with no indication of an exhausted condition. MACD indicator with the histogram reading at 0.053 and the 12-day and 26-day EMAs at -0.084 and -0.137, respectively, must return above the 0 level to confirm the upward momentum. Slow Stochastic indicator with readings so far of 64.71 %K and 65.52 %D, reflects a bullish signal with no confirmation of an exhausted condition. With share prices hitting the stock’s 52-week low of 2.12 last March 17, a significant support level or buying entry point was established, pushing up prices 23.58 percent to their present level.

GREM, USA, Inc. (GRMU) TraderNote GRMU Hosted Premier Guitar Magazine (”Premier”) Representatives at its Fort Wayne, Indiana Facility

GREM, USA, Inc. (GRMU) closed yesterday at 0.0033, a positive change of 0.00070 or an increase of 26.92 percent from the previous close of 0.00070. GREM, USA, Inc., a development stage company, engages in the design and manufacture of custom handmade and mass-produced electronic guitars, amplifiers, and accessories. The company is based in Fort Wayne, Indiana. GREM, USA recently announced that on April 1, 2008, GREM management hosted Premier Guitar Magazine (”Premier”) representatives at its Fort Wayne, Indiana production facility in an enthusiastic and overwhelmingly positive initial meeting to discuss the company’s line of guitars, production methods, and the company vision. The company is pleased to note that Premier staff, having first-hand familiarity of the company’s designs and production capability, has asked to spend an additional day at the GREM facility to expand their future feature story on the company in Premier’s popular online and print magazine. In yesterday’s daily chart, GRMU’s RSI indicator so far reflects a reading of 39.94 percent, with no indication of an exhausted condition and with the line horizontally-oriented. MACD indicator with the histogram reading at 0.005 and the 12-day and 26-day EMAs at -0.012 and -0.016, respectively, must return above the 0 level to sustain the upward momentum. Slow Stochastic indicator with readings so far of 49.58 %K and 38.36 %D, is approaching the neutral level with the lines steeply directed towards the 50 percent level. With share prices hitting the stock’s 52-week low of 0.0006 last Feb. 27, a significant support level or buying entry point was established pushing up prices 450 percent to their present level.

Packeteer, Inc. (PKTR) TraderNote PKTR Shares Soared After Rejecting a $5.50 a Share Hostile Takeover Offer from Elliott Associates

Packeteer, Inc. (PKTR) closed yesterday at 5.74 percent, a positive change of 0.51 or an increase of 9.75 percent from the previous close of 5.23. Packeteer, Inc., together with its subsidiaries, provides wide area network application delivery systems. The company’s products include PacketShaper, which provides application traffic monitoring services, visibility into network utilization and application performance and enables service providers to create differentiated services through bandwidth provisioning and management. Its products also include iShared that is suited for environments with collaborative traffic, such as files, email, and documents, as well as undergoing server consolidation and Mobiliti software, which provides solutions for the mobile users and small office/home offices, as well as delivers a software-based client solution installed on laptops and personal computers. The company offers SkyX products and technologies for Internet and private network access, accelerating applications to data center links, disaster recovery architectures, and satellite and long-haul networks. It sells its products through a network of distributors, value-added resellers, and system integrators. The company’s products are deployed by data centers, branch office sites, software clients, enterprise customers, and information technology organizations. PKTR shares soared after it rejected a $5.50 a share hostile takeover offer, valued at $200.8 million, from Elliott Associates late yesterday. The fact that Packeteer’s shares traded significantly higher than the $5.50 a share offer price indicates shareholders agree with the firm that it is worth more. In yesterday’s daily chart, almost all technical indicators of PKTR are in the positive zone. The RSI indicator, with a reading so far of 64.57 percent, reflects a bullish signal with the line steeply directed upwards. MACD indicator reflects a strong bullish signal with the histogram reading above the 0 level at 0.037 and the 12-day and 26-day EMAs also above 0 at 0.164 and 0.127, respectively, indicating an increase in moving averages. Slow Stochastic indicator with readings so far of 58.31%K and 56.26 %D, is in the bullish but near neutral zone. The same chart reflects a technical trading gap formed by April 1st ’s close at 5.23 and yesterday’s open at 5.57, indicating a strong bullish signal as initiated by an upward reversal of the stock. With share prices hitting the stock’s 52-week low of 3.81 last March 4, a significant support level or buying entry point was established pushing up prices 50.66 percent to their present level.

Cell Therapeutics, Inc. (CTIC) TraderNote EMEA Accepted for Review CTIC’s MMA for XYOTAX (paclitaxel poliglumex, CT-2103) for Treatment of Lung Cancer

Cell Therapeutics, Inc. (CTIC) closed yesterday at 0.84, a positive change of 0.17 or an increase of 25.19 percent from the previous close of 0.67. Cell Therapeutics, Inc. markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-Hodgkin’s lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. Cell Therapeutics recently announced that the European Medicines Agency (EMEA) has accepted for review CTI’s Marketing Authorization Application (MAA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) with Eastern Cooperative Oncology Group (ECOG) performance status 2 (PS2). CTI submitted the MAA at the beginning of March. The validation of the MAA for XYOTAX initiates the marketing approval review process, which generally takes 15 to 18 months. The application is based on advice from the Scientific Advice Working Party, or SAWP, at the EMEA. In yesterday’s daily chart, CTIC’s RSI indicator reflects a reading so far of 49.55 percent, near the neutral zone with no indication of an exhausted condition. MACD indicator so far reflects a weak bullish signal with the histogram reading above the 0 level at 0.050 and the 12-day and 26-day EMAs below 0 at -0.129 and -0.179, respectively. Slow Stochastic indicator with readings so far of 68.61 %K and 67.35 %D, reflects a bullish signal with no indication of an exhausted condition. The same chart also reflects a technical trading gap formed by April 1st ’s close and yesterday’s open at 0.85, indicating a strong bullish signal as initiated by an upward reversal. With share prices hitting the stock’s 52-week low of 0.47 last March 19, a significant support level or buying entry point was established, pushing up prices 78.72 percent to their present level.

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of China Nuvo Solar Energy, Inc. (OTCBB: CNUV). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts’ personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (Beacon) certifies that no part of the analysts’ compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research and its affiliates have been directly compensated twelve thousand five hundred dollars from a non-controlling third party for enrollment of CNUV in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.